Thank you for your interest in submitting an abstract to the 22nd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP) to be held April 7-10, 2019, in Salt Lake City, Utah. Posters will be displayed April 8 and 9 and published on cpnp.org and in the May 2019 issue of the Mental Health Clinician. Continue to the abstract submission center.
The 2019 Poster Presenter Handbook
provides the most important details for abstract authors. It contains deadlines, submission requirements, poster guidelines, and example abstracts. Download it and review the information carefully.
Accepted Abstract Categories
- Original Research: Abstracts should describe original research in therapeutics, pharmacodynamics, pharmacoeconomics, outcomes, drug utilization, kinetics, genetics and academic pursuits. Abstracts must not have been published in abstract form nor presented as a poster elsewhere before the CPNP 2019 Meeting.
- Encore Presentation: Abstracts of papers that have been previously presented and peer reviewed. Submission must include where it was previously presented or the abstract will be disqualified. Encore submissions are not eligible for any of the award categories and should not be submitted for award consideration.
- Work in Progress (WIP): Abstracts describing preliminary results or status of ongoing work may be submitted by principal investigators at any stage of their career. Abstracts submitted without results at the time of submission will be considered for this category only.
- Innovative Practices: Abstracts describing the development, justification, documentation, and/or delivery of innovative services or activities applicable to psychiatric and neurologic pharmacy. The descriptive abstract should not duplicate any other poster category and should describe the development of innovative services/activities and should provide background/rationale, a description of the innovative service, the impact on patient care/institution and a conclusion.
- Therapeutic Case Report: Abstracts describing the various aspects of pharmaceutical care relating to individual psychiatric and/or neurological pharmacy cases. Abstracts should provide a complete patient history including age, gender, time from first diagnosis, social background, and details of, and response to, previous and current treatment(s). Cases should include background, complete patient history, review of literature, and conclusion.